在NSCLC中,MUC1-C是获得的奥西米尔丁尼布耐药性的常见驱动因素
Naoki Haratake1, Hiroki Ozawa1, Yoshihiro Morimoto1
1Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
概括
在非小细胞肺癌 (NSCLC) 中,MUC1-C 是 osimertinib 耐药性的关键驱动因素. 向MUC1-C可以逆转耐药性,并为EGFR突变NSCLC患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物耐药性 药物耐药性 药物耐药性
背景情况:
- 奥西默提尼布是转移性非小细胞肺癌 (NSCLC) 的第一线治疗方法,具有特定的EGFR突变.
- 对奥西默蒂尼布的获得性耐药性通过各种机制发展,包括EGFR突变和MET放大.
- 瘤性MUC1-C蛋白在 osimertinib 耐药性的作用以前是未知的.
研究的目的:
- 为了研究耐奥西默提尼布NSCLC细胞对MUC1-C的依赖性.
- 为了确定MUC1-C是否是获得的 osimertinib 耐药性的常见机制.
- 评估MUC1-C作为克服奥西默提尼布耐药性的潜在治疗标.
主要方法:
- 研究了NSCLC细胞系中MUC1-C的依赖性,这些细胞系具有获得的奥西默提尼布耐药性 (H1975-OR,MGH700-2D,MGH170-1D #2,MGH121 Res#2).
- 评估了EGFR通路激活 (p-EGFR,p-ERK,p-AKT),表皮质-介质酶过渡 (EMT),克隆原性和自我更新能力.
- 检查了MUC1-C向对实验室中 osimertinib 耐药性的影响.
主要成果:
- MUC1-C在耐奥西默提尼布NSCLC细胞中升级调节,对于EGFR通路激活至关重要.
- 在各种耐药模型中,MUC1-C是维持耐药表型,EMT和自我更新能力所必需的.
- 针对MUC1-C有效地逆转了在多个耐药NSCLC模型中的osimertinib耐药性.
- 高MUC1表达与EGFR突变NSCLC患者的预后不佳相关.
结论:
- MUC1-C是NSCLC中获得的 osimertinib 耐药性的常见和关键调解者.
- MUC1-C代表了治疗耐奥西默提尼布耐药NSCLC患者的有希望的治疗标.
- 针对MUC1-C提供了一种潜在的策略,以克服耐药性并改善NSCLC患者的治疗结果.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.3K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K